1 of 1
HOUSE DOCKET, NO. 2589 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 2500
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Thomas W. Moakley and Julian Cyr
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act relative to increasing access to epinephrine.
_______________
PETITION OF:
NAME:DISTRICT/ADDRESS :DATE ADDED:Thomas W. MoakleyBarnstable, Dukes and Nantucket1/16/2025 1 of 3
HOUSE DOCKET, NO. 2589 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 2500
By Representative Moakley of Falmouth and Senator Cyr, a joint petition (accompanied by bill,
House, No. 2500) of Thomas W. Moakley relative to increasing access to epinephrine. Public
Health.
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Fourth General Court
(2025-2026)
_______________
An Act relative to increasing access to epinephrine.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 SECTION 1. Chapter 111 of the General Laws is hereby amended by inserting after
2section 4O the following section:-
3 Section 4P. (a) As used in this section, the following words shall have the following
4meanings unless the context clearly requires otherwise:
5 "Authorized entity" means any entity or organization at which allergens capable of
6causing anaphylaxis may be present, including, but not limited to, restaurants, recreation camps,
7youth sports leagues, amusement parks, colleges, universities, and sports arenas.
8 "Epinephrine autoinjector" means a single-use device used for the automatic injection of
9a premeasured dose of epinephrine into the human body
10 (b) An authorized entity may acquire and maintain a supply of epinephrine autoinjectors
11from a wholesaler approved by the department pursuant to this section. All acquired epinephrine 2 of 3
12autoinjectors shall be stored in a location readily accessible in an emergency and in accordance
13with the epinephrine autoinjector's instructions for use. An authorized entity shall designate
14employees or agents who have completed the training required by subsection (d) of this section
15to be responsible for the storage, maintenance and general oversight of epinephrine autoinjectors
16acquired under this section.
17 (c) An employee or agent of an authorized entity who has completed the training required
18by subsection (d) of this section may, on the premises of or in connection with the authorized
19entity, use epinephrine autoinjectors obtained under this section to provide or administer an
20epinephrine autoinjector to any individual who the employee or agent believes in good faith is
21experiencing anaphylaxis for immediate self-administration, regardless of whether the individual
22has a prescription for an epinephrine autoinjector or has previously been diagnosed with an
23allergy.
24 (d) An employee, agent, or other individual described in subsection (c) of this section
25must complete an anaphylaxis training program prior to providing or administering an
26epinephrine autoinjector made available by an authorized entity. The training must be conducted
27by a nationally recognized organization experienced in training laypersons in emergency health
28treatment or by an entity or individual approved by the department of public health. The entity
29shall submit proof of training to the department and receive approval for the acquisition of
30epinephrine autoinjectors.
31 (e) An authorized entity that possesses and makes available epinephrine autoinjectors and
32its trained employees and agents shall not liable for any injuries or related damages that result
33from the administration or self-administration of an epinephrine autoinjector, the failure to 3 of 3
34administer an epinephrine autoinjector, or any other act or omission taken pursuant to this
35section, provided that said immunity does not apply to acts or omissions constituting gross
36negligence or willful or wanton misconduct.
37 (f) An authorized entity that possesses and makes available epinephrine autoinjectors
38shall submit to the department of public health, on a form developed by the department, a report
39of each incident on the authorized entity's premises that involves the distribution or
40administration of the authorized entity's epinephrine autoinjector. The department of public
41health shall annually publish a report that summarizes and analyzes all reports submitted to it
42under this subsection.
43 (g) The department shall promulgate guidance or regulations to carry out this section.